Skip to main content

Table 1 Demographics of patients in the discovery and validation populations

From: Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

  Discovery data set Validation data set
Number of patients 210 150
Age, median (range) years 59 (22–90) 53 (18–89)
Gender n (%)
 Male 117 (56%) 94 (63%)
 Female 93 (44%) 56 (37%)
Objective Response n (%)
 Patient responsive 28 (13%) 20 (13%)
 Patients non-responsive 182 (87%) 130 (87%)
One-year Survival n (%)
 Patient alive at one year 118 (56%) 43 (29%)
 Patient deceased at one year 92 (44%) 107 (71%)
 Prior chemotherapy No Yes
Stage of disease n (%)
 IIIC 13 (6%) 5 (3%)
 IV M1A 35 (17%) 16 (11%)
 IV M1B 49 (23%) 30 (20%)
 IV M1C 113 (54%) 99 (66%)
Live in United States n (%)
 U.S. 44 (21%) 62 (41%)
 Non-U.S. 166 (79%) 88 (59%)